Expression_NN
of_IN
1,25_CD
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
receptors_NNS
on_IN
alveolar_JJ
lymphocytes_NNS
from_IN
patients_NNS
with_IN
pulmonary_JJ
granulomatous_JJ
diseases_NNS
._.

1,25_CD
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
is_VBZ
known_VBN
to_TO
be_VB
produced_VBN
at_IN
sites_NNS
of_IN
granulomatous_JJ
reactions_NNS
._.

In_IN
order_NN
to_TO
characterize_VB
the_DT
cell_NN
types_NNS
that_WDT
are_VBP
targets_NNS
for_IN
this_DT
immunoregulatory_JJ
hormone_NN
,_,
we_PRP
have_VBP
evaluated_VBN
the_DT
expression_NN
of_IN
1,25_CD
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
receptors_NNS
on_IN
peripheral_JJ
blood_NN
T-lymphocytes_NNS
and_CC
those_DT
recovered_VBN
from_IN
the_DT
lung_NN
by_IN
bronchoalveolar_JJ
lavage_NN
from_IN
patients_NNS
with_IN
pulmonary_JJ
granulomatous_JJ
diseases_NNS
-LRB-_-LRB-
tuberculosis_NN
and_CC
sarcoidosis_NN
-RRB-_-RRB-
and_CC
from_IN
normal_JJ
control_NN
subjects_NNS
using_VBG
combined_JJ
autoradiographic_JJ
and_CC
immunohistochemical_JJ
techniques_NNS
._.

Lavage_NN
T-lymphocytes_NNS
from_IN
patients_NNS
with_IN
tuberculosis_NN
or_CC
with_IN
sarcoidosis_NN
,_,
but_CC
not_RB
those_DT
from_IN
normal_JJ
control_NN
subjects_NNS
,_,
expressed_VBD
1,25_CD
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
receptors_NNS
as_IN
demonstrated_VBN
by_IN
binding_NN
of_IN
-LCB-_-LRB-
3H-RCB-1_NN
,25_NN
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
,_,
which_WDT
was_VBD
inhibited_VBN
by_IN
the_DT
presence_NN
of_IN
excess_JJ
unlabeled_JJ
1,25_CD
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
,_,
but_CC
not_RB
by_IN
the_DT
presence_NN
of_IN
unlabeled_JJ
25_CD
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
D3_NN
-LRB-_-LRB-
receptor-positive_JJ
lymphocytes_NNS
:_:
sarcoidosis_NN
,_,
20_CD
+_CC
\/_CD
-_:
12_CD
%_NN
;_:
tuberculosis_NN
,_,
31_CD
+_CC
\/_CD
-_:
17_CD
%_NN
-RRB-_-RRB-
._.

In_IN
contrast_NN
,_,
blood_NN
lymphocytes_NNS
from_IN
patients_NNS
with_IN
granulomatous_JJ
diseases_NNS
did_VBD
not_RB
express_VB
detectable_JJ
1,25_CD
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
receptors_NNS
._.

The_DT
percentage_NN
of_IN
lavage_NN
T-lymphocytes_NNS
expressing_VBG
1,25_CD
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
receptors_NNS
was_VBD
significantly_RB
greater_JJR
for_IN
patients_NNS
with_IN
tuberculosis_NN
presenting_VBG
with_IN
isolated_VBN
hilar_JJ
adenopathy_NN
than_IN
for_IN
patients_NNS
with_IN
pulmonary_JJ
infiltrates_NNS
and\/or_CC
cavities_NNS
._.

1,25_NN
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
receptors_NNS
were_VBD
expressed_VBN
to_TO
a_DT
greater_JJR
extent_NN
on_IN
CD8_NN
+_CC
T-lymphocytes_NNS
than_IN
on_IN
CD4_NN
+_CC
T-lymphocytes_NNS
in_IN
sarcoidosis_NN
,_,
whereas_IN
a_DT
greater_JJR
proportion_NN
of_IN
CD4_NN
+_CC
than_IN
of_IN
CD8_NN
+_CC
T-lymphocytes_NNS
from_IN
patients_NNS
with_IN
tuberculosis_NN
were_VBD
receptor-positive_JJ
._.

These_DT
findings_NNS
support_VBP
the_DT
conclusion_NN
that_IN
the_DT
interaction_NN
of_IN
1,25_CD
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
with_IN
its_PRP$
receptor_NN
on_IN
T-lymphocytes_NNS
may_MD
play_VB
an_DT
important_JJ
role_NN
in_IN
the_DT
regulation_NN
of_IN
granulomatous_JJ
reactions_NNS
,_,
but_CC
because_IN
these_DT
receptors_NNS
are_VBP
expressed_VBN
on_IN
different_JJ
lymphocyte_NN
populations_NNS
,_,
the_DT
net_JJ
effect_NN
of_IN
this_DT
potent_JJ
immunoregulatory_JJ
molecule_NN
is_VBZ
likely_RB
different_JJ
in_IN
sarcoidosis_NN
and_CC
tuberculosis_NN
._.

